$12.05
3.88% today
NYSE, Dec 04, 10:00 pm CET
ISIN
US29089Q1058
Symbol
EBS

Emergent Biosolutions Inc Stock price

$11.60
+1.11 10.58% 1M
+5.19 80.97% 6M
+2.04 21.34% YTD
+2.31 24.87% 1Y
-0.19 1.61% 3Y
-70.85 85.93% 5Y
-22.98 66.45% 10Y
+0.55 4.98% 20Y
NYSE, Closing price Wed, Dec 03 2025
+0.75 6.91%
ISIN
US29089Q1058
Symbol
EBS
Industry

Key metrics

Basic
Market capitalization
$609.2m
Enterprise Value
$1.0b
Net debt
$417.6m
Cash
$245.5m
Shares outstanding
52.7m
Valuation (TTM | estimate)
P/E
8.7 | 5.6
P/S
0.8 | 0.7
EV/Sales
1.3 | 1.3
EV/FCF
733.5
P/B
1.1
Financial Health
Equity Ratio
34.7%
Return on Equity
-39.5%
ROCE
8.3%
ROIC
7.0%
Debt/Equity
1.1
Financials (TTM | estimate)
Revenue
$788.9m | $816.0m
EBITDA
$175.2m | $187.6m
EBIT
$110.1m | $90.4m
Net Income
$75.9m | $109.1m
Free Cash Flow
$1.4m
Growth (TTM | estimate)
Revenue
-29.9% | -21.8%
EBITDA
444.9% | 1,243.7%
EBIT
195.1% | 210.9%
Net Income
136.4% | 157.3%
Free Cash Flow
-99.0%
Margin (TTM | estimate)
Gross
54.6%
EBITDA
22.2% | 23.0%
EBIT
14.0%
Net
9.6% | 13.4%
Free Cash Flow
0.2%
More
EPS
$1.3
FCF per Share
$0.0
Short interest
17.8%
Employees
900
Rev per Employee
$1.2m
Show more

Is Emergent Biosolutions Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,088 stocks worldwide.

Emergent Biosolutions Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Emergent Biosolutions Inc forecast:

5x Buy
71%
1x Hold
14%
1x Sell
14%

Analyst Opinions

7 Analysts have issued a Emergent Biosolutions Inc forecast:

Buy
71%
Hold
14%
Sell
14%

Financial data from Emergent Biosolutions Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
789 789
30% 30%
100%
- Direct Costs 358 358
52% 52%
45%
431 431
14% 14%
55%
- Selling and Administrative Expenses 206 206
39% 39%
26%
- Research and Development Expense 50 50
45% 45%
6%
175 175
445% 445%
22%
- Depreciation and Amortization 65 65
0% 0%
8%
EBIT (Operating Income) EBIT 110 110
195% 195%
14%
Net Profit 76 76
136% 136%
10%

In millions USD.

Don't miss a Thing! We will send you all news about Emergent Biosolutions Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Emergent Biosolutions Inc Stock News

Neutral
GlobeNewsWire
16 days ago
GAITHERSBURG, Md., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Today Emergent BioSolutions (NYSE: EBS) recognizes the 10-year anniversary of the U.S. Food and Drug Administration (FDA) approval of NARCAN® (naloxone HCl) Nasal Spray as the first FDA-approved nasal naloxone spray for emergency treatment of opioid overdose.
Neutral
GlobeNewsWire
22 days ago
GAITHERSBURG, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS) announced today that Dr. Louis W.
Positive
Seeking Alpha
28 days ago
Emergent BioSolutions maintains a Buy rating, supported by recent Q3 earnings beat and CEO Joe Papa's turnaround progress. EBS reported Q3 revenues of $231.1M and net income of $51.2M, surpassing guidance, with improved capital allocation and reduced net debt. Narcan sales declined year-over-year due to pricing and volume pressures, but sequential growth and strong demand signal market stabiliz...
More Emergent Biosolutions Inc News

Company Profile

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It offers specialty products for civilian and military populations that address accidental, intentional and naturally occurring public health threats. The firm's products include ACAM2000, BioThrax, Raxibacuma, Vaxchora, and VIGIV. Its business units include Vaccines and Anti-Infectives; Antibody Therapeutics; Devices; and Contract Development and Manufacturing. The company was founded by Fuad El-Hibri in May 1998 and is headquartered in Gaithersburg, MD.

Head office United States
CEO Joseph Papa
Employees 900
Founded 1998
Website emergentbiosolutions.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today